Physician profile
Fabio A Piazza
NPI 1023226958
$1,436.50
in general payments reported to CMS, 2019-2025
21 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.55 · 2020: $57.87 · 2021: $209 · 2022: $231 · 2023: $88.65 · 2024: $338 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $337.10 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $319.40 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Intra-Sana Laboratories | $145.51 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Nevro Corp. | $121.06 | 2022 | |
| Pfizer INC. | $103.32 | 2019-2022 | |
| Amgen INC. | $86.77 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $58.25 | 2020-2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.42 | 2024-2025 | Jardiance, Synjardy |
| Kowa Pharmaceuticals America, INC. | $25.78 | 2021-2022 | |
| Amarin Pharma, INC. | $25.71 | 2019-2021 | |
| Exact Sciences Corporation | $21.18 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $19.80 | 2021 | |
| Daiichi Sankyo INC. | $15.28 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.11 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $14.77 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $14.52 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.94 | 2022 | |
| Abbvie INC. | $13.63 | 2021 | |
| Glaxosmithkline, LLC. | $13.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.69 | 2019 | |
| Merck Sharp & Dohme LLC | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fabio Piazza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.